Suicidal behaviour and SSRIs: updated meta-analysisBMJ 2006; 332 doi: http://dx.doi.org/10.1136/bmj.332.7555.1453-a (Published 15 June 2006) Cite this as: BMJ 2006;332:1453
- Julia Saperia, research assistant (email@example.com),
- Deborah Ashby, professor of medical statistics,
- David Gunnell, professor of epidemiology
- Wolfson Institute of Preventive Medicine, Queen Mary, University of London, London EC1M 6BQ
- Department of Social Medicine, University of Bristol, Bristol BS8 2PR
EDITOR—Our meta-analysis on the risk of suicide from selective serotonin reuptake inhibitors (SSRIs) was published last year.1 In the light of recently released data for paroxetine by its manufacturer, GlaxoSmithKline,2 we have updated our results.
In our original analysis we were unable to distinguish between occurrences of non-fatal self harm and suicidal thoughts for patients in paroxetine trials. Our main analysis of these events therefore excluded the paroxetine data; in a sensitivity analysis we divided the events equally between self harm and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial